Pharma Q4 Earnings Preview - 2021 To End On A Strong Note: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Aided by lower overheads and strong traction in their India and active pharmaceutical ingredient businesses, Q4 FY21 adjusted profits of the companies we cover are expected to have averaged faster, 23%, growth to Rs 22.9 billion.
Their Q4 FY21 revenues are expected to have averaged 8% YoY growth to Rs 152 billion.
Their India/API sales are expected to have grown 9.8%/17% while their U.S. sales could have declined 5.6% to $421 million.
Ebitda margins are expected at a high 24.1%, a 246 basis point rise from a year ago; sequentially, though, they may decline 178 bps due to rise in promotional expenses.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.